Visit https://www.peervoice.com/VVA860 to view the entire programme with slides. After completing “Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC”, participants will be able to: Describe the unmet needs for patients with advanced NSCLC and how checkpoint inhibitors can address these challenges; Evaluate the most recent clinical evidence for current and emerging checkpoint inhibitors in the first-line management of advanced NSCLC with high PD-L1 expression; Discuss how emerging data may impact the treatment algorithm for patients with advanced NSCLC and high PD-L1 expression.

Visit https://www.peervoice.com/ABV860 to view the entire programme with slides. After completing “"Improving Outcomes in Early-Stage EGFR-Mutant NSCLC: What Pathologists Can Do"”, participants will be able to: Discuss recent clinical data on the management of early-stage EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with early-stage EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

Visit https://www.peervoice.com/SBV860 to view the entire programme with slides. After completing “Reassessing What’s Possible in Early-Stage EGFR-mutant NSCLC: Insights from the Latest Data ”, participants will be able to: Discuss recent clinical data on the management of early-stage EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with early-stage EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

Visit https://www.peervoice.com/UBY860 to view the entire programme with slides. After completing “Best Practices in Early-Stage EGFR-Mutant NSCLC: What Surgeons Need to Know”, participants will be able to: Discuss the role of the thoracic surgeon in the management of early-stage EGFR-mutant NSCLC, Explain best practices for resection and adjuvant therapy for patients with early-stage EGFR-mutant NSCLC, Formulate strategies to improve communication and collaboration among the multidisciplinary team.

Visit https://www.peervoice.com/ESR860 to view the entire programme with slides. After completing “Evolving Treatment Paradigm in Early-Stage EGFR-Mutant NSCLC: A Primer for Medical Oncologists”, participants will be able to: Discuss recent clinical data on the management of early-stage EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with early-stage EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

Visit https://www.peervoice.com/CHA860 to view the entire programme with slides. After completing “Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists”, participants will be able to: Discuss recent clinical data on the management of early-stage EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with early-stage EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

Visit https://www.peervoice.com/VDG860 to view the entire programme with slides. After completing “Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists”, participants will be able to: Discuss recent clinical data on the management of localised EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with localised EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

Visit https://www.peervoice.com/FEW860 to view the entire programme with slides. After completing “Setting New Goals for Slowing Progression in Chronic Kidney Disease: What Is Possible With GLP-1 RAs?”, participants will be able to: Explain the rationale for the current focus on slowing the progression of chronic kidney disease (CKD) in patients with type 2 diabetes (T2DM); Evaluate the use of GLP-1 RAs as part of a for multifactorial management plan for patients with T2DM and CKD; Formulate treatment plans incorporating current guideline recommendations to slow the progression of CKD in patients with T2DM.

Visit https://www.peervoice.com/PTD860 to view the entire programme with slides. After completing “Understanding Hypercapnia in Adult Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes”, participants will be able to: Explain the impact of hypercapnia on critically ill patients within the intensive care setting; Identify patients who would be candidates for low-flow extracorporeal carbon dioxide removal (ECCO2R); Evaluate how to appropriately integrate low-flow ECCO2R techniques in clinical practice.

Visit https://www.peervoice.com/FKG860 to view the entire programme with slides. After completing “GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!”, participants will be able to: Differentiate between GnRH antagonists and LHRH agonists; Describe the recent clinical trial data assessing GnRH antagonist therapy for the treatment of prostate cancer; Discuss if GnRH antagonist therapy may lead to different clinical outcomes.